Clinical Trials Logo

Filter by:
NCT ID: NCT00827606 Completed - Clinical trials for Familial Hypercholesterolemia

Atorvastatin Three Year Pediatric Study

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial Hypercholesterolemia receiving atorvastatin treatment.

NCT ID: NCT00825955 Completed - Liver Cancer Clinical Trials

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

BRISK PS
Start date: February 17, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib

NCT ID: NCT00824460 Completed - Clinical trials for Chronic Kidney Disease

Study of Phosphate Levels in Patients With Chronic Kidney Disease

PA21
Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.

NCT ID: NCT00824265 Completed - Clinical trials for Leukaemia, Lymphocytic, Chronic

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Start date: March 12, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT00823992 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Start date: January 2009
Phase: Phase 3
Study type: Interventional

This 2 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Patients will be randomized to receive taspoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) or placebo sc, in addition to their prescribed, pre-existing metformin therapy.After the first 24 weeks, patients on placebo will be switched to taspoglutide 20mg once weekly (after 4 weeks on taspoglutide 10mg once weekly) The anticipated time on study treatment is 12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00822744 Completed - Clinical trials for Major Depressive Disorder

An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients

FIDELIO
Start date: December 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton Depression Rating Scale. Secondary objectives are: - To evaluate the tolerability and safety of an 8-week treatment with SSR411298 versus placebo in elderly patients with MDD. - To evaluate the effect of SSR411298 on disability, anxiety, cognitive function, sleep, pain and somatic symptoms related to depression, and bone markers. - To assess SSR411298 plasma concentrations. - To assess plasma endocannabinoid concentrations.

NCT ID: NCT00820222 Completed - Metastases, Brain Clinical Trials

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Start date: April 14, 2009
Phase: Phase 3
Study type: Interventional

This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.

NCT ID: NCT00819585 Completed - Gout Clinical Trials

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy. The core study was followed by a 24-week open-label, multicenter extension study to assess the safety, tolerability, and efficacy of canakinumab in patients with gout who were given canakinumab at the time of gout flare.

NCT ID: NCT00819156 Completed - Prostate Cancer Clinical Trials

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of the trial was to evaluate the safety and efficacy of degarelix when comparing six different doses. The patients participating in the trial were treated with degarelix every month for a year. During the treatment the patients had to visit the clinic for investigations. Blood samples for testosterone, dihydrotestosterone, luteinizing hormone, follicle stimulating hormone, and Prostate Specific Antigen were taken and analysed throughout the trial.

NCT ID: NCT00819091 Completed - Clinical trials for Diabetes Mellitus, Type 2

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Start date: December 2008
Phase: Phase 3
Study type: Interventional

Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.